"...drug maker Valeant Pharmaceuticals 'VRX.T +0.16% $11 billion acquisition of specialist drug maker Salix Pharmaceuticals; AbbVie ABBV +0.16%’s acquisition of cancer biotech company Pharmacyclics for $21 billion; and also the decision by U.S. pharmacy benefit manager UnitedHealth UNH +0.41% to buy rival Catamaran for $12.8 billion."
http://blogs.wsj.com/moneybeat/2015/08/10/health-care-deals-prop-up-hedge-funds-that-bet-on-ma/
No comments:
Post a Comment